BR0012006A - Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr - Google Patents

Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr

Info

Publication number
BR0012006A
BR0012006A BR0012006-5A BR0012006A BR0012006A BR 0012006 A BR0012006 A BR 0012006A BR 0012006 A BR0012006 A BR 0012006A BR 0012006 A BR0012006 A BR 0012006A
Authority
BR
Brazil
Prior art keywords
ltbr
tumor growth
autoimmune diseases
suppress
substances
Prior art date
Application number
BR0012006-5A
Other languages
English (en)
Inventor
Daniela N Monnel
Thomas Hehlgans
Carola Seitz
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999129488 external-priority patent/DE19929488A1/de
Priority claimed from DE2000104447 external-priority patent/DE10004447A1/de
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR0012006A publication Critical patent/BR0012006A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO PARA EVITAR INFLAMAçõES, DOENçAS AUTOIMUNES E CRESCIMENTO DE TUMOR, E, USO DE SUBSTâNCIAS QUE SUPRIMEM A ATIVAçãO MEDIADA POR LTBR". Método para evitar inflamações, doenças autoimunes e crescimento de tumor em que se suprime a ativação mediada por LTBR.
BR0012006-5A 1999-06-28 2000-06-21 Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr BR0012006A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999129488 DE19929488A1 (de) 1999-06-28 1999-06-28 Verfahren zur Verhinderung von Tumorwachstum
DE2000104447 DE10004447A1 (de) 2000-02-03 2000-02-03 Verfahren zur Verhinderung von Tumorwachstum
PCT/EP2000/005738 WO2001000228A1 (de) 1999-06-28 2000-06-21 Verfahren zur verhinderung von tumorwachstum

Publications (1)

Publication Number Publication Date
BR0012006A true BR0012006A (pt) 2002-03-12

Family

ID=26004148

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012006-5A BR0012006A (pt) 1999-06-28 2000-06-21 Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr

Country Status (20)

Country Link
EP (1) EP1189626B1 (pt)
JP (1) JP3822822B2 (pt)
KR (1) KR20020016852A (pt)
CN (1) CN1359297A (pt)
AT (1) ATE410180T1 (pt)
AU (1) AU5406000A (pt)
BG (1) BG106246A (pt)
BR (1) BR0012006A (pt)
CA (1) CA2376920A1 (pt)
DE (1) DE50015391D1 (pt)
ES (1) ES2313893T3 (pt)
HK (1) HK1047045A1 (pt)
HU (1) HUP0201804A2 (pt)
IL (1) IL147180A0 (pt)
MX (1) MXPA01013367A (pt)
NO (1) NO20016380D0 (pt)
PL (1) PL353057A1 (pt)
SK (1) SK18852001A3 (pt)
TR (1) TR200103841T2 (pt)
WO (1) WO2001000228A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134994A0 (en) 2000-03-09 2001-05-20 Yeda Res & Dev Coupled two way clustering analysis of data
AU2003292696A1 (en) 2002-12-26 2004-08-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
BRPI0512397A (pt) 2004-06-25 2008-03-04 Takeda Pharmaceutical composto,produto farmacêutico, métodos para suprimir a metástase de cáncer ou o crescimento do cáncer, para prevenir ou tratar uma doença ou condição, para controlar a função placentária, para melhorar a função gonadal, para induzir ou estimular a ovulação, para promover a secreção do hormÈnio gonadotrópico ou promover a secreção do hormÈnio sexual, para suprimir a secreção do hormÈnio gonadotrópico ou suprimir a secreção do hormÈnio sexual, para infra regular hormÈnio gonadrotópico ou hormÈnio sexual, e a proteìna ot7t175 humana, e para realçar a estabilidade no sangue, uso do composto, e, agente para suprimir a secreção do hormÈnio gonadotrópico ou um agente para suprimir a secreção do hormÈnio sexual
CA2624730A1 (en) * 2005-10-04 2007-04-12 The John Hopkins University Compositions and methods for treating inflammation
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
WO2008083169A2 (en) * 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
NZ335353A (en) * 1996-10-25 2000-09-29 Biogen Inc Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases including AIDS or HIV
DK1051187T3 (da) * 1998-01-30 2004-03-08 Univ New York Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen

Also Published As

Publication number Publication date
TR200103841T2 (tr) 2002-06-21
JP2003503359A (ja) 2003-01-28
WO2001000228A1 (de) 2001-01-04
NO20016380L (no) 2001-12-27
PL353057A1 (en) 2003-10-06
NO20016380D0 (no) 2001-12-27
IL147180A0 (en) 2002-08-14
HUP0201804A2 (en) 2002-09-28
ATE410180T1 (de) 2008-10-15
EP1189626A1 (de) 2002-03-27
AU5406000A (en) 2001-01-31
DE50015391D1 (de) 2008-11-20
SK18852001A3 (sk) 2002-12-03
BG106246A (bg) 2002-10-31
HK1047045A1 (zh) 2003-02-07
JP3822822B2 (ja) 2006-09-20
CN1359297A (zh) 2002-07-17
MXPA01013367A (es) 2002-07-02
EP1189626B1 (de) 2008-10-08
KR20020016852A (ko) 2002-03-06
CA2376920A1 (en) 2001-01-04
ES2313893T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
PT777482E (pt) Composicao de combinacao para utilizacao em doencas imunologicas
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
AR009356A1 (es) Compuesto de 1-4 heterociclico, inhibidor de la metaloproteasa y su uso para preparar una composicion farmaceutica y para prevenir o tratar una enfermedad asociada con la actividad de la metalo proteasa y la caquexia
DK0880350T3 (da) Behandling af dissemineret sklerose
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
PT902789E (pt) Derivados de androsteno
EA200101089A1 (ru) Новый способ лечения
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
MY138883A (en) Use of asiatic acid for treatment of cencer
SE9802208D0 (sv) Novel compounds
AU3611299A (en) Use of metalloprotinease inhibitors for inducing and/or stimulating growth of hair or hairs and/or for slowing down their loss
PT706385E (pt) Utilizacao de isovaleramida como agente ansiolitico suave e como agente sedativo suave
BR0014758A (pt) Sistemas e métodos para expressão de proteìna com alto rendimento
BR0012006A (pt) Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
ITRM970731A0 (it) Composizione per il trattamento di ustioni eritemi solari abrasioni piaghe e irritazioni cutanee
ES2174533T3 (es) Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
SE9802209D0 (sv) Novel compounds
ES2162410T3 (es) Uso de alcohol diclorobencilico para hacer una preparacion para tratamiento topico de inflamacion.
GB9626472D0 (en) New use of comt inhibitors
PT841937E (pt) Utilizacao de betaglicano para reduzir a formacao de cicatrizes
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
IT1251497B (it) Uso di 1,2 dipalmitoil-l-alfa-fosfatidil-n,n-dimetiletanolammina, in composizioni dermatologiche
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
ES2171080T3 (es) Composicion para la mejora de la fertilidad y su aplicacion.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007.